# Akribion Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/akribion-therapeutics

- Industry: Biotechnology
- Headquarters: Zwingenberg, Germany
- Website: www.akribion-therapeutics.com
- Total disclosed funding: $8.4M
- Latest round: Seed (Jan 24, 2025)
- Investors on record: 5

## About

Founded in 2024 in Zwingenberg, Germany, Akribion Therapeutics specializes in RNA-guided enzyme technologies. The company has secured one deal to date, raising EUR 8.000 mn in Seed funding on February 4, 2025, with notable investors including Bruker Invest AG and High-Tech Grunderfonds. The founder’s specific background is not detailed, and no mergers, carve-outs, or parent companies have been referenced. Lukas Linning co-founded the firm and led the firm as Co-CEO as of 2025.

Akribion Therapeutics utilizes a proprietary G-dase® E payload technology designed for programmable cell depletion. This method selectively targets unwanted cells by matching guide RNA with intracellular RNA, primarily focusing on HPV-induced Oropharyngeal Head & Neck Cancer (OPSCC) while exploring applications in oncology, autoimmune diseases, and infectious diseases. The company aims its services at healthcare providers and research institutions across Europe and North America. 

Akribion Therapeutics generates revenue through strategic partnerships and licensing agreements related to its G-dase® E technology. Revenue streams may include milestone payments and royalties from product sales, emphasizing B2B transactions with healthcare institutions rather than direct consumer sales.

## Funding rounds

- Seed, Jan 24, 2025, $8.4M — High-Tech Gruenderfonds, BMH, CARMA FUND Management, Bruker, RV Invest

## Investors

- High-Tech Gruenderfonds (https://capitalatlas.ai/funds/high-tech-gruenderfonds) — Seed
- BMH (https://capitalatlas.ai/funds/bmh) — Seed
- CARMA FUND Management (https://capitalatlas.ai/funds/carma-fund-management) — Seed
- Bruker — Seed
- RV Invest (https://capitalatlas.ai/funds/rv-invest) — Seed